ProCE Banner Activity

Experts Answer Questions on Managing mCRPC in a Rapidly Evolving Disease Paradigm

Clinical Thought
In this commentary, experts provide answers to audience questions from a live webinar on the latest developments in managing patients with metastatic castration-resistant prostate cancer in a rapidly evolving disease paradigm.

Released: March 14, 2022

Expiration: March 13, 2023

No longer available for credit.

Share

Faculty

Matthew R. Smith

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Michael Schweizer

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Novartis Pharmaceuticals Corp Advanced Accelerator Applications

Sanofi Genzyme

Program Director Disclosure

Program Director

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has disclosed that he has received consultant/advisor/speaker fees from Amgen, Astellas, Bayer, Janssen, Lilly, and Pfizer.

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento, and Tempus.

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael Schweizer, MD, has disclosed that he has received consulting fees from AstraZeneca, PharmaIn, and Sanofi and funds for research support paid to his institution from Ambrx, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Immunomedics, Janssen, Madison Vaccines, Merck, Pfizer, SignalOne Bio, Tmunity, and Zenith Epigenetics.